Pharma stock investing: Biogen vs AstraZeneca

Biogen has had its breakthrough Alzheimer’s drug approved and AstraZeneca has several exciting drugs in development. Are these pharma stocks buys for me?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

US pharma stock Biogen (NASDAQ:BIIB) recently made history having its Alzheimer’s drug Aduhelm approved. It’s the first Alzheimer’s therapy drug to be approved in over 20 years. So, does this mean Biogen is worth adding to my Stocks and Shares ISA?

So much promise

While Aduhelm doesn’t cure Alzheimer’s, it claims to halt it, which promises a better quality of life for millions of sufferers. But its fast-tracked approval is a controversial decision, and many health professionals are unimpressed.

In fact, three FDA members have gone so far as to resign in response to the decision. That’s because it’s not completed all phases of trial that drugs usually have to go through. Accelerated approval appears to be triggered because those in need are desperately clinging to the hope it can bring.

Biogen will continue to pursue efficacy trials, but the results are likely to take years, and in the meantime, it’s free to sell and profit from the drug.

Unfortunately, like many new drugs, Aduhelm is expensive. But, at $56k a year, it’s eye-wateringly so. In fact, this is a new extreme for drug pricing and likely to receive extreme pushback from authorities in the future.

Nevertheless, approval is set to mean at least some sales. And these are predicted to reach between a potential $7.5bn and $50bn a year.

A boost to the Biogen share price

The Biogen share price has already soared in response. At almost $385, it’s up 33% in a week, but down 18% since its peak on 10 June. A year ago it was $260.

If the drug meets positive expectations, it could be a game-changer for Biogen and its stock price. But it remains under scrutiny, and if it doesn’t meet expectations, I think the share price is likely to take a hit.

With the Aduhelm news cushioning the share price, other bad news seems to be flying under the radar. In the past week, Biogen reported failed trial results in three pipeline drugs; another potential Alzheimer’s drug, an eye treatment, and a drug for depression. While the share price seems buoyant for now, these failures remind us of biotech shares’ risk.

It’s also a highly competitive industry, and other major players are lining up their versions of Alzheimer’s drugs for FDA approval.

When investing in biotech/pharma stocks, I prefer big established companies over growth stocks. For that reason, I’d potentially allocate a small number of Biogen shares to my portfolio. But I also like AstraZeneca (LSE: AZN) as a significant pharma player.

AstraZeneca has a lot to offer

AstraZeneca has seen its share price fluctuate in recent months. Today it’s trading around £83 a share, which is down 17% from its 52-week-high and up 24% from its 52-week-low.

Its collaboration with Oxford University to bring a Covid-19 vaccine to market has not gone as smoothly as hoped, which has affected the AZN share price along the way. Nevertheless, the FTSE 100 company has more to offer.

AstraZeneca has a highly revered division focused on developing cancer therapies. It also has a diabetes treatment, heart failure therapy, and respiratory drugs. Additionally, it’s in the process of acquiring Alexion, a company specialising in rare diseases.

Q1 results showed signs of growth and rising revenues. I think both companies have potential. But I’d choose AstraZeneca over Biogen as it feels like a steadier long-term investment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended Biogen. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

Here’s another top buy from the FTSE 250 I’m considering

Oliver Rodzianko considers this FTSE 250 company a stellar choice for his portfolio. It's on his growth watchlist; so let's…

Read more »

A young Asian woman holding up her index finger
Investing Articles

A “once in a lifetime” opportunity for Rolls-Royce shares?

One firm is hoping now is a “once in a lifetime” opportunity for UK nuclear companies. Our writer reveals whether…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

The IAG share price is dirt cheap and profits are flying. So why am I worried?

After today's positive full-year results, I expected the International Consolidated Airlines Group (IAG) share price to be doing better than…

Read more »

Investing Articles

Is Tesla stock a steal below $200?

Tesla stock has fallen 19% so far in 2024. Currently hovering around $200, this Fool checks if now is the…

Read more »

Investing Articles

3 high-yield dividend stocks to consider for my passive income portfolio in 2024

I want to build a portfolio of dividend stocks that pay enough passive income to retire comfortably. Here are my…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Direct Line shares soar 25% on takeover bid!

Direct Line shares surged by a quarter on Wednesday, after receiving a takeover bid from a Belgian rival. But the…

Read more »

Investing Articles

Will it be too late to buy Nvidia stock in March?

NVIDIA stock is up more than 60% since the start of 2024. Our writer considers whether it might still be…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

Why did Direct Line shares just soar 27%?

Direct Line shares have jumped more than a quarter in the course of today's trading session. Our writer explains why…

Read more »